Shuttle Pharmaceuticals Holdings Key Executives
This section highlights Shuttle Pharmaceuticals Holdings's key executives, including their titles and compensation details.
Find Contacts at Shuttle Pharmaceuticals Holdings
(Showing 0 of )
Shuttle Pharmaceuticals Holdings Earnings
This section highlights Shuttle Pharmaceuticals Holdings's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
$0.39
Stock Price
$2.43M
Market Cap
9
Employees
Rockville, MD
Location
Financial Statements
Access annual & quarterly financial statements for Shuttle Pharmaceuticals Holdings, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $6.81K | $66.83K | $60.83K | $54.95K |
| Gross Profit | $- | $-6.81K | $-66.83K | $-60.83K | $-54.95K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $3.62B | $3.52M | $1.49M | $1.02M | $161.77K |
| General and Administrative Expenses | $1.39B | $1.05M | $1.07M | $721.18K | $347.75K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.39B | $1.05M | $1.07M | $721.18K | $347.75K |
| Other Expenses | $2.68B | $1.33M | $328.69K | $- | $- |
| Operating Expenses | $7.70B | $5.89M | $2.55M | $1.74M | $509.52K |
| Cost and Expenses | $- | $5.89M | $2.55M | $1.74M | $509.52K |
| Interest Income | $38.14M | $79.12K | $- | $- | $- |
| Interest Expense | $-8.69M | $2.60M | $969.89K | $50.79K | $39.63K |
| Depreciation and Amortization | $- | $6.81K | $5.97K | $60.83K | $54.95K |
| EBITDA | $-7.70B | $-3.99M | $-4.32M | $-1.04M | $-711.15K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-7.70B | $-5.89M | $-2.55M | $-1.74M | $-509.52K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-1.45B | $-700.34K | $-474.17K | $590.86K | $-296.21K |
| Income Before Tax | $-9.14B | $-6.59M | $-3.03M | $-1.15M | $-805.73K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $71.01K | $50.79K | $39.63K |
| Net Income | $-9.14B | $-6.59M | $-3.10M | $-1.20M | $-845.36K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-3186.21 | $-0.41 | $-0.30 | $-0.09 | $-0.06 |
| EPS Diluted | $-3167.28 | $-0.41 | $-0.30 | $-0.09 | $-0.06 |
| Weighted Average Shares Outstanding | 2.87M | 15.91M | 10.35M | 13.59M | 13.59M |
| Weighted Average Shares Outstanding Diluted | 2.89M | 15.91M | 10.35M | 13.59M | 13.59M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $9.66K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $962 | $1.91K | $1.98K | $1.86K | $1.48K | $1.49K | $17.34K | $- | $- | $16.05K | $16.38K | $- | $- | $18.91K |
| Gross Profit | $- | $- | $-962 | $-1.91K | $7.67K | $-1.86K | $-1.48K | $-1.49K | $-17.34K | $- | $- | $-16.05K | $-16.38K | $- | $- | $-18.91K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 79.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $986.41K | $1.40M | $645.72K | $586.10K | $432.61K | $1.14M | $933.37K | $1.01M | $439.71K | $669.04K | $83.87K | $295.92K | $442.12K | $186.96K | $286.73K | $106.00K |
| General and Administrative Expenses | $790.72K | $329.00K | $310.04K | $798.74K | $850.22K | $458.84K | $532.26K | $533.97K | $301.08K | $152.43K | $269.76K | $342.48K | $546.41K | $55.16K | $49.52K | $70.09K |
| Selling and Marketing Expenses | $- | $- | $525.91K | $472.22K | $-1.98K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $790.72K | $329.00K | $836.91K | $796.83K | $848.24K | $458.84K | $532.26K | $533.97K | $301.08K | $152.43K | $269.76K | $342.48K | $546.41K | $55.16K | $49.52K | $70.09K |
| Other Expenses | $- | $1.32M | $- | $474.13K | $255.71K | $288.42K | $416.69K | $367.62K | $866.77K | $328.69K | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $1.78M | $3.05M | $1.48M | $1.38M | $1.28M | $1.60M | $1.47M | $1.54M | $740.79K | $821.47K | $353.63K | $638.40K | $988.54K | $242.12K | $336.25K | $176.09K |
| Cost and Expenses | $1.78M | $3.05M | $1.48M | $1.38M | $1.28M | $1.60M | $1.47M | $1.54M | $740.79K | $821.47K | $353.63K | $638.40K | $988.54K | $242.12K | $336.25K | $176.09K |
| Interest Income | $3 | $2.52K | $14.16K | $21.45K | $22.40K | $20.77K | $19.27K | $16.69K | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $159.28K | $272.68K | $430.69K | $497.51K | $532.05K | $623.47K | $731.94K | $603.57K | $10.12K | $618.44K | $185.23K | $156.10K | $18.68K | $10.66K | $10.67K | $10.78K |
| Depreciation and Amortization | $1.80K | $793 | $962 | $1.91K | $1.98K | $1.86K | $1.48K | $1.49K | $17.34K | $1.58K | $1.45K | $16.05K | $16.38K | $15.18K | $10.37K | $18.91K |
| EBITDA | $-1.44M | $-3.51M | $-1.60M | $-1.23M | $-1.11M | $-1.17M | $-1.45M | $-370.04K | $-723.45K | $-379.98K | $-412.05K | $-509.69K | $-423.99K | $-206.30K | $-325.88K | $-99.63K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -13264.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-1.78M | $-3.05M | $-1.48M | $-1.38M | $-1.28M | $-1.60M | $-1.47M | $-1.54M | $-740.79K | $-821.47K | $-353.63K | $-638.40K | $-988.54K | $-242.12K | $-336.25K | $-176.09K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -13285.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $178.66K | $-732.52K | $-548.58K | $-346.18K | $-357.68K | $-193.61K | $-718.74K | $569.68K | $-10.12K | $-176.96K | $-243.65K | $-43.44K | $529.49K | $25.16K | $-10.55K | $46.76K |
| Income Before Tax | $-1.60M | $-3.78M | $-2.03M | $-1.73M | $-1.64M | $-1.79M | $-2.18M | $-975.10K | $-750.91K | $-998.42K | $-597.27K | $-681.84K | $-459.05K | $-216.96K | $-346.80K | $-129.32K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -16989.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $- | $-2 | $-3 | $17.50K | $731.94K | $-1.26M | $71.01K | $966.60K | $243.65K | $43.44K | $18.68K | $10.66K | $10.67K | $10.78K |
| Net Income | $-1.60M | $-3.78M | $-2.03M | $-1.73M | $-1.64M | $-1.79M | $-2.18M | $285.71K | $-821.92K | $-1.02M | $-840.92K | $-725.28K | $-459.05K | $-216.96K | $-346.80K | $-129.32K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -16989.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.56 | $-1.59 | $-0.96 | $-0.10 | $-0.10 | $-0.11 | $-0.15 | $0.02 | $-0.06 | $-0.10 | $-0.06 | $-0.05 | $-0.03 | $-0.02 | $-0.03 | $-0.01 |
| EPS Diluted | $-0.55 | $-1.59 | $-0.96 | $-0.10 | $-0.10 | $-0.11 | $-0.15 | $0.02 | $-0.06 | $-0.10 | $-0.06 | $-0.05 | $-0.03 | $-0.02 | $-0.03 | $-0.01 |
| Weighted Average Shares Outstanding | 2.87M | 2.38M | 2.10M | 16.57M | 16.07M | 15.74M | 14.26M | 13.64M | 13.60M | 10.16M | 13.28M | 13.28M | 13.59M | 13.28M | 13.28M | 13.28M |
| Weighted Average Shares Outstanding Diluted | 2.89M | 2.38M | 2.10M | 16.57M | 16.07M | 15.74M | 14.26M | 13.64M | 13.60M | 10.16M | 13.28M | 13.28M | 13.59M | 13.28M | 13.28M | 13.28M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.92B | $2.58M | $8.42M | $504.75K | $117.15K |
| Short Term Investments | $- | $2.89M | $- | $- | $- |
| Cash and Short Term Investments | $1.92B | $5.46M | $8.42M | $504.75K | $117.15K |
| Net Receivables | $- | $14.90K | $- | $- | $211.46K |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $290.77M | $114.47K | $161.15K | $4.87K | $12.58K |
| Total Current Assets | $2.21B | $5.59M | $8.58M | $509.62K | $341.19K |
| Property Plant Equipment Net | $295.37K | $358.73K | $68.71K | $135.55K | $196.38K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $295.08M | $- | $6.48K | $6.48K | $6.48K |
| Total Non-Current Assets | $295.37M | $358.73K | $75.19K | $142.03K | $202.86K |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $2.51B | $5.95M | $8.65M | $651.64K | $544.05K |
| Account Payables | $596.60K | $283.31K | $129.25K | $828.31K | $516.97K |
| Short Term Debt | $1.41B | $648.48K | $811.12K | $916.43K | $686.44K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $378.56K | $228.39K |
| Other Current Liabilities | $119.61M | $110.45K | $35.31K | $472.58K | $901.56K |
| Total Current Liabilities | $1.53B | $1.04M | $975.68K | $2.22M | $2.10M |
| Long Term Debt | $238.33M | $439.22K | $- | $62.44K | $129.38K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $25.04M | $414.51K | $- | $- | $- |
| Total Non-Current Liabilities | $263.37M | $853.73K | $865.04K | $62.44K | $129.38K |
| Other Liabilities | $- | $- | $-865.04K | $- | $- |
| Total Liabilities | $1.80B | $1.90M | $975.68K | $2.28M | $2.23M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $41 | $20 | $136 | $93 | $93 |
| Retained Earnings | $-34.58B | $-25.43M | $-8.89M | $-5.80M | $-4.54M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $16.34K | $16.34K |
| Other Total Stockholders Equity | $35.29B | $29.49M | $26.52M | $4.17M | $2.85M |
| Total Stockholders Equity | $709.15M | $4.06M | $7.68M | $-1.63M | $-1.69M |
| Total Equity | $709.15M | $4.06M | $7.68M | $-1.63M | $-1.69M |
| Total Liabilities and Stockholders Equity | $2.51B | $5.95M | $8.65M | $651.64K | $544.05K |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $2.51B | $5.95M | $8.65M | $651.64K | $544.05K |
| Total Investments | $- | $2.89M | $- | $- | $- |
| Total Debt | $1.65B | $1.09M | $748.30K | $978.88K | $815.82K |
| Net Debt | $-268.55M | $-1.49M | $-7.67M | $474.13K | $698.66K |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.92M | $156.66K | $695.59K | $1.40M | $2.58M | $3.89M | $5.45M | $7.17M | $8.42M | $9.12M | $50.44K | $405.86K | $504.75K |
| Short Term Investments | $- | $- | $1.64M | $2.79M | $2.89M | $2.92M | $2.90M | $2.99M | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.92M | $156.66K | $2.34M | $4.19M | $5.46M | $6.81M | $8.35M | $10.16M | $8.42M | $9.12M | $50.44K | $405.86K | $504.75K |
| Net Receivables | $- | $4 | $7.23K | $11.96K | $14.90K | $12.44K | $6.95K | $7.02K | $- | $5.95K | $- | $- | $- |
| Inventory | $- | $- | $- | $1 | $- | $170.10K | $78.95K | $-7.02K | $- | $- | $- | $- | $- |
| Other Current Assets | $290.77K | $204.69K | $139.52K | $129.64K | $114.47K | $176.58K | $85.43K | $203.84K | $161.15K | $163.14K | $13.52K | $20.61K | $4.87K |
| Total Current Assets | $2.21M | $361.35K | $2.49M | $4.33M | $5.59M | $7.00M | $8.44M | $10.37M | $8.58M | $9.29M | $63.95K | $426.47K | $509.62K |
| Property Plant Equipment Net | $295.37K | $312.22K | $327.67K | $342.90K | $358.73K | $380.21K | $393.76K | $50.93K | $68.71K | $86.05K | $103.05K | $119.50K | $135.55K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $- | $81.53K | $- | $- | $- | $13.69K | $6.48K | $6.48K | $6.48K | $6.48K | $6.48K |
| Total Non-Current Assets | $295.37K | $312.22K | $327.67K | $424.44K | $358.73K | $380.21K | $393.76K | $64.62K | $75.19K | $92.53K | $109.53K | $125.98K | $142.03K |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $2.51M | $673.57K | $2.81M | $4.75M | $5.95M | $7.38M | $8.84M | $10.44M | $8.65M | $9.38M | $173.48K | $552.45K | $651.64K |
| Account Payables | $596.60K | $1.35M | $364.89K | $347.56K | $283.31K | $180.00K | $88.74K | $447.47K | $129.25K | $107.15K | $515.79K | $691.20K | $828.31K |
| Short Term Debt | $935.38K | $308.65K | $950.42K | $1.05M | $700.96K | $523.86K | $390.46K | $846.13K | $811.12K | $832.89K | $1.33M | $1.18M | $916.43K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $-62.09K | $- | $- | $-180.00K | $-88.74K | $- | $- | $- | $- | $- | $378.56K |
| Other Current Liabilities | $1.78K | $2.14K | $69.31K | $91.16K | $57.97K | $106.58K | $14.48K | $94.75K | $35.31K | $30.43K | $605.55K | $485.23K | $472.58K |
| Total Current Liabilities | $1.53M | $1.66M | $1.38M | $1.49M | $1.04M | $810.44K | $493.68K | $1.39M | $975.68K | $970.47K | $2.45M | $2.36M | $2.22M |
| Long Term Debt | $238.09K | $255.60K | $267.02K | $288.60K | $439.22K | $442.81K | $452.08K | $751.69K | $- | $6.67K | $25.60K | $44.25K | $62.44K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $25.28K | $74.11K | $359.92K | $214.62K | $414.51K | $512.83K | $955.73K | $1.39M | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $263.37K | $329.71K | $626.94K | $503.22K | $853.73K | $955.63K | $1.41M | $2.14M | $865.04K | $6.67K | $25.60K | $44.25K | $62.44K |
| Other Liabilities | $- | $- | $- | $- | $1 | $- | $- | $- | $-865.04K | $- | $- | $- | $- |
| Total Liabilities | $1.80M | $1.99M | $2.01M | $1.99M | $1.90M | $1.77M | $1.90M | $3.53M | $975.68K | $977.14K | $2.48M | $2.40M | $2.28M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $41 | $29 | $21 | $168 | $161 | $160 | $155 | $137 | $136 | $136 | $93 | $93 | $93 |
| Retained Earnings | $-34.58M | $-32.98M | $-29.20M | $-17.22M | $-15.49M | $-13.85M | $-12.05M | $-9.87M | $-8.89M | $-8.14M | $-7.13M | $-6.50M | $-5.80M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $16.34K |
| Other Total Stockholders Equity | $35.29M | $31.66M | $30.00M | $19.98M | $29.49M | $19.46M | $18.99M | $16.78M | $16.57M | $16.55M | $4.82M | $4.65M | $4.17M |
| Total Stockholders Equity | $709.15K | $-1.32M | $801.43K | $2.76M | $4.06M | $5.61M | $6.94M | $6.91M | $7.68M | $8.40M | $-2.31M | $-1.85M | $-1.63M |
| Total Equity | $709.15K | $-1.32M | $801.43K | $2.76M | $4.06M | $5.61M | $6.94M | $6.91M | $7.68M | $8.40M | $-2.31M | $-1.85M | $-1.63M |
| Total Liabilities and Stockholders Equity | $2.51M | $673.57K | $2.81M | $4.75M | $5.95M | $7.38M | $8.84M | $10.44M | $8.65M | $9.38M | $173.48K | $552.45K | $651.64K |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $2.51M | $673.57K | $2.81M | $4.75M | $5.95M | $7.38M | $8.84M | $10.44M | $8.65M | $9.38M | $173.48K | $552.45K | $651.64K |
| Total Investments | $- | $- | $1.64M | $2.79M | $2.89M | $2.92M | $2.90M | $2.99M | $- | $- | $- | $- | $- |
| Total Debt | $1.17M | $564.26K | $1.16M | $1.28M | $1.09M | $966.67K | $781.51K | $1.55M | $748.30K | $765.85K | $1.36M | $1.23M | $978.88K |
| Net Debt | $-746.67K | $407.60K | $459.76K | $-114.08K | $-1.49M | $-2.92M | $-4.67M | $-5.62M | $-7.67M | $-8.35M | $1.31M | $819.73K | $474.13K |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-9.14M | $-6.59M | $-3.03M | $-1.15M | $-805.73K |
| Depreciation and Amortization | $5.46M | $6.81K | $66.83K | $60.83K | $54.95K |
| Deferred Income Tax | $- | $- | $- | $-641.65K | $- |
| Stock Based Compensation | $259.74M | $181.96K | $403.96K | $910.07K | $459.59K |
| Change in Working Capital | $138.91K | $220.63K | $-555.21K | $519.15K | $7.78K |
| Accounts Receivables | $- | $- | $- | $211.46K | $164.93K |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $313.30K | $154.06K | $-382.88K | $311.35K | $-51.13K |
| Other Working Capital | $-174.38K | $66.57K | $-172.32K | $-3.65K | $-106.02K |
| Other Non Cash Items | $-7.58B | $602.17K | $402.41K | $3.39K | $256.58K |
| Net Cash Provided by Operating Activities | $-7.33B | $-5.58M | $-2.71M | $-300.34K | $-26.83K |
| Investments in Property Plant and Equipment | $- | $-19.05K | $- | $- | $-10.82K |
| Acquisitions Net | $- | $3.02M | $- | $- | $- |
| Purchases of Investments | $-43.59K | $-3.00M | $- | $- | $- |
| Sales Maturities of Investments | $2.96B | $187.90K | $- | $- | $- |
| Other Investing Activities | $-43.54M | $-3.02M | $- | $- | $- |
| Net Cash Used for Investing Activities | $2.92B | $-2.83M | $- | $- | $-10.82K |
| Debt Repayment | $133.46K | $2.92M | $600.72K | $687.93K | $70.07K |
| Common Stock Issued | $3.99M | $2.70M | $10.00M | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $-402.07K | $- | $- |
| Other Financing Activities | $3.75B | $-345.00K | $428.75K | $- | $- |
| Net Cash Used Provided by Financing Activities | $3.76B | $2.57M | $10.62M | $687.93K | $70.07K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-656.27M | $-5.84M | $7.91M | $387.60K | $32.42K |
| Cash at End of Period | $1.92B | $2.58M | $8.42M | $504.75K | $117.15K |
| Cash at Beginning of Period | $2.58B | $8.42M | $504.75K | $117.15K | $84.73K |
| Operating Cash Flow | $-7.33B | $-5.58M | $-2.71M | $-300.34K | $-26.83K |
| Capital Expenditure | $- | $-19.05K | $- | $- | $-10.82K |
| Free Cash Flow | $-7.33B | $-5.60M | $-2.71M | $-300.34K | $-37.65K |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-1.60M | $-3.78M | $-2.03M | $-1.73M | $-1.64M | $-1.79M | $-2.18M | $-975.10K | $-750.91K | $-998.42K | $-597.27K | $-681.84K | $-459.05K | $-216.96K | $-346.80K | $-129.32K |
| Depreciation and Amortization | $1.80K | $793 | $962 | $1.91K | $1.98K | $1.86K | $1.48K | $1.49K | $17.34K | $1.58K | $16.45K | $16.05K | $16.38K | $15.18K | $10.37K | $18.91K |
| Deferred Income Tax | $- | $- | $- | $- | $10.35K | $-409.09K | $6.07K | $- | $555.21K | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $31.86K | $45.27K | $71.16K | $111.45K | $86.52K | $37.58K | $49.52K | $8.33K | $47.22K | $23.67K | $166.53K | $166.53K | $542.52K | $122.52K | $122.52K | $122.52K |
| Change in Working Capital | $-940.14K | $993.68K | $41.19K | $44.17K | $173.47K | $35.07K | $-288.57K | $300.66K | $6.48K | $-255.50K | $-148.51K | $-142.26K | $309.79K | $97.54K | $173.01K | $-61.19K |
| Accounts Receivables | $4 | $7.22K | $4.74K | $2.94K | $-2.47K | $-5.49K | $- | $- | $5.95K | $-5.95K | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $-5.49K | $5.49K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-751.84K | $983.55K | $58.87K | $22.72K | $103.31K | $91.26K | $-358.73K | $318.23K | $9.59K | $-79.95K | $-175.41K | $-137.12K | $307.70K | $103.89K | $-42.06K | $-58.19K |
| Other Working Capital | $-188.30K | $2.91K | $-22.42K | $18.52K | $72.63K | $-56.19K | $70.16K | $-17.57K | $-9.06K | $-1.33K | $26.89K | $-5.14K | $2.09K | $-6.35K | $215.07K | $-3.01K |
| Other Non Cash Items | $-185.21K | $745.69K | $518.56K | $424.03K | $306.00K | $592.40K | $769.81K | $-673.37K | $-555.21K | $290.91K | $207.39K | $16.91K | $-544.79K | $-35.81K | $-117 | $-57.54K |
| Net Cash Provided by Operating Activities | $-2.69M | $-2.00M | $-1.40M | $-1.24M | $-1.06M | $-1.53M | $-1.65M | $-1.34M | $-679.87K | $-1.05M | $-355.42K | $-624.61K | $-135.15K | $-17.54K | $-41.02K | $-106.62K |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $19.05K | $-19.05K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $35.98K | $-17.28K | $-18.70K | $-20.86K | $-6.81K | $-17.20K | $-2.95M | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $1.66M | $1.18M | $120.00K | $107.89K | $- | $80.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-43.59K | $- | $-18.70K | $-3.02M | $- | $- | $-2.95M | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $- | $1.66M | $1.16M | $101.30K | $87.04K | $-25.86K | $62.80K | $-2.95M | $- | $- | $- | $- | $- | $- | $- | $- |
| Debt Repayment | $730.27K | $-95.14K | $-501.67K | $- | $-334.44K | $- | $-139.23K | $3.04M | $- | $75.00K | $- | $525.72K | $494.93K | $120.00K | $- | $73.01K |
| Common Stock Issued | $- | $1.58M | $40.00K | $325.30K | $2.59M | $- | $- | $104.55K | $-23.32K | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $-402.07K | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $3.72M | $-101.65K | $40.00K | $-40.00K | $- | $- | $- | $- | $- | $10.05M | $- | $- | $- | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $4.45M | $-196.79K | $-461.67K | $-40.00K | $-334.44K | $- | $-139.23K | $3.04M | $-23.32K | $10.12M | $- | $525.72K | $494.93K | $120.00K | $- | $73.01K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $1.76M | $-538.94K | $-703.03K | $-1.18M | $-1.31M | $-1.56M | $-1.72M | $-1.25M | $-703.19K | $9.07M | $-355.42K | $-98.89K | $359.77K | $102.46K | $-41.02K | $-33.62K |
| Cash at End of Period | $1.92M | $156.66K | $695.59K | $1.40M | $2.58M | $3.89M | $5.45M | $7.17M | $8.42M | $9.12M | $50.44K | $405.86K | $504.75K | $144.97K | $42.52K | $83.54K |
| Cash at Beginning of Period | $156.66K | $695.59K | $1.40M | $2.58M | $3.89M | $5.45M | $7.17M | $8.42M | $9.12M | $50.44K | $405.86K | $504.75K | $144.97K | $42.52K | $83.54K | $117.15K |
| Operating Cash Flow | $-2.69M | $-2.00M | $-1.40M | $-1.24M | $-1.06M | $-1.53M | $-1.65M | $-1.34M | $-679.87K | $-1.05M | $-355.42K | $-624.61K | $-135.15K | $-17.54K | $-41.02K | $-106.62K |
| Capital Expenditure | $- | $-2 | $2 | $- | $19.05K | $-19.05K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $-2.69M | $-2.00M | $-1.40M | $-1.24M | $-1.04M | $-1.55M | $-1.65M | $-1.34M | $-679.87K | $-1.05M | $-355.42K | $-624.61K | $-135.15K | $-17.54K | $-41.02K | $-106.62K |
Shuttle Pharmaceuticals Holdings Dividends
Explore Shuttle Pharmaceuticals Holdings's dividend history, including dividend yield, payout ratio, and historical payments.
Shuttle Pharmaceuticals Holdings News
Read the latest news about Shuttle Pharmaceuticals Holdings, including recent articles, headlines, and updates.
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today the closing of its previously announced underwritten public offering of 19,166,667 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.30 per share (the “Offering”). The aggregate gross proceeds to Shuttle Pharma from the Offering was approximately $5.75 million, before deducting underwriting discounts and commissions and other offering expenses payable by Shuttle Pharma.
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today the pricing of an underwritten public offering of 19,166,667 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.30 per share (the “Offering”). The aggregate gross proceeds to Shuttle Pharma from the Offering are expected to be approximately $5.75 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Shuttle Pharma. The Offering is expected to close on March 13, 2025, subject to the satisfaction of customary closing conditions.
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activities Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activities
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
GAITHERSBURG, Md., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2024.
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
GAITHERSBURG, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that CEO, Anatoly Dritschilo, M.D., will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today first patient enrollment and dosing at the UVA Cancer Center in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma. UVA is one of six cancer centers conducting the clinical trials. Shuttle Pharma previously announced the dosing of patients at Miami Cancer Institute, part of Baptist Health South Florida.
Shuttle Pharma Provides Third Quarter 2024 Corporate Update
GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2024.
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the pricing of its "reasonable best efforts" public offering with a health-care focused institutional investor for the purchase and sale of up to 2,950,820 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,950,820 shares of common stock at a combined offering price of $1.525 per share and accompanying warrant, priced at-the-market under Nasdaq rules (the “Offering”). The Company expects to receive aggregate gross proceeds of approximately $4.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants will have an exercise price of $1.40 per share, will be exercisable immediately and will expire five years from the issuance date.
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has finalized agreements with all six of the planned site enrollment locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma following the entry into agreements with Georgetown University Medical Center and UNC Medical Center. The Company previously entered agreements with UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network (AHN) Cancer Institute, and Miami Cancer Institute, part of Baptist Health South Florida. Patients are currently undergoing screening for enrollment in the trial.
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two additional site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Four of the planned six trial sites are now prepared to enroll patients in the clinical trial, including the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network (AHN) Cancer Institute, and Miami Cancer Institute, part of Baptist Health South Florida.
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2024.
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today reports that it received formal notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Q2 Quarterly Report”).
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two of the six site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Site initiation visits have been completed for two sites. The trial is now open to enroll patients in the clinical trial.
Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of one of the Company's HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC).
Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
Shuttle Pharma Provides First Quarter 2024 Corporate Update
GAITHERSBURG, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024.
Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
GAITHERSBURG, Md., April 23, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”), today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will present at the Planet MicroCap Showcase: VEGAS 2024, on Wednesday, May 1, 2024 at 4:30pm PT. The Company will also host in person one-on-one meetings with investors on Thursday, May 2, 2024.
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024
GAITHERSBURG, Md., April 03, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”), today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference.
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
GAITHERSBURG, Md., March 21, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023.
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
ROCKVILLE, Md. , Feb. 13, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("SHPH" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), along with its wholly-owned subsidiary, Shuttle Diagnostics, Inc., a Maryland corporation ("Diagnostics"), today announced its intent to commence a Rights Offering where it plans to raise up to $4.5 million through the distribution of subscription rights and the exercise thereof, which full rights will entitle existing SHPH stockholders to purchase from the Company units (the "Units"), with each Unit consisting of (i) one share of SHPH common stock, (ii) a warrant to purchase one share of SHPH common stock exercisable at a per share purchase price of $2.35 per share, and (iii) a percentage of equity interest in Diagnostics.
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
ROCKVILLE, Md. , Jan. 23, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference, taking place virtually on February 1, 2024.
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
ROCKVILLE, Md. , Jan. 8, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced they have received the 'Safe to Proceed' letter from the U.S. Food and Drug Administration (FDA) for the Company's investigational new drug (IND) application for its Phase II study of Ropidoxuridine (IPdR) as a radiation sensitizing agent during radiotherapy in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter.
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
ROCKVILLE, Md. , Dec. 11, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to support the next phase of development of Ropidoxuridine.
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023
Webcasted presentation to take place at 10:15am ET ROCKVILLE, Md. , Nov. 30, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy ("RT") (the "Company" or "Shuttle Pharmaceuticals"), today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference on December 7, 2023 (the "Conference").
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
ROCKVILLE, Md. , Nov. 14, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
ROCKVILLE, Md. , Oct. 31, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered into an exclusive agreement to license certain intellectual property (IP) from Georgetown University to advance Shuttle Pharma's predictive biomarker program for prostate cancer.
Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference
ROCKVILLE, Md. , Oct. 10, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
Company remains on track to initiate the clinical trial in Q4 of 2023 ROCKVILLE, Md. , Sept. 25, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application (PIND) meeting with the U.S. Food and Drug Administration (FDA).
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for SHPH.